Diagnosis and Management of Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:1158-1192, Saposnik,G.,et al, 2011
Thrombosis of the Cerebral VEins and Sinuses
NEJM 352:1791-1798, Stam,J., 2005
Imaging of Cerebral Isolated Cortical Vein Thrombosis
AJR 184:1317-1319, Duncan,I.C.&Fourie,P.A., 2005
Cerebral Venous Thrombosis: Influence of Risk Factors and Imaging Findings on Prognosis
Clin Neurol Neurosurg 107:371-378, Appenzeller,S.,et al, 2005
Cerebral Venous Sinus Thrombosis Associated with Factor V Gene Mutation
JNNP 61:204-205, Kimber,T.,et al, 1996
Cerebral Venous Thrombosis
Neurol Clin 10:87-111, Ameri,A.&Bousser,M-G., 1992
MR of Deep Cerebral Venous Thrombosis
Can J Neurol Sci 16:417-421, Ashforth,R.A.,et al, 1989
Atypical Parkinsonian Syndromes: A General Neurologists Perspective
Eur J Neurol 25:41-58, Deutschlander, A.B.,et al, 2018
Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016
Paraneoplastic Cerebellar Degeneration with Anti-Yo Antibodies - A Review
Ann Clin Trans Neurol 3:655-663, Venkatraman,A. & Opal,P., 2016
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015
Safety and Efficacy of Ofatumumab in Relapsing-Remitting Multiple Sclerosis
Neurol 82:573-581, Sorensen, P.S.,et al, 2014
Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 381:2167-2175, Gold, R.,et al, 2013
Natalizumab-Associated PML Identified in the Presymptomatic Phase Using MRI Surveillance
Neurol 78:507-508, Blair,N.F.,et al, 2012
Late onset autism and anti-NMDA-receptor encephalitis
Lancet 378:98;378, Creten, C.,et al, 2011
Neurosacrcoidosis: Presentations and Management
Neurologist 16:2-15, Terushkin,V.,et al, 2010
Reversible Paraneoplpastic Limbic Encephalitis Associated with Antibodies to the AMPA Receptor
Neurol 74:265-267, Bataller,L.,et al, 2010
Response to Immunotherapy in a 20-Month-Old Boy With Anti-NMDA Receptor Encephalitis
Neurol 74:1550-1551, Wong-Kisiel,L.C., et al, 2010
Prolactinomas
NEJM 362:1219-1226, Klibanski,A., 2010
A Case of Neurosarcoidosis Successfully Treated with Rituximab
Neurol 75:568-570, Bomprezzi,R., et al, 2010
JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
Treatment of CNS Sarcoidosis with Infliximab and Mycophenolate Mofetil
Neurol 72:337-340, Morovan,M. &Segal,B.M., 2009
Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study
Arch Neurol 66:593-599, Boster,A.,et al, 2009
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis
NEJM 358:676-688, Hauser,S.L.,et al, 2008
Postwithdrawal Rebound Increase in T2 Lesional Activity in Natalizumab-Treated MS Patients
Neurol 70:1150-1151,1073, Vellinga,M.M.,et al, 2008
Clinicopath Conf., Endheim-Chester Disease
NEJM 359:736-747, Case 25-2008, 2008
Anti-Tumor Necrosis Factor Alpha-Associated Multiple Sclerosis
AJNR 26:1548-1550, Titelbaum,D.S.,et al., 2008
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008
Daclizumab Phase II Trial in Relapsing and Remitting Multiple Sclerosis
Neurol 69:785-789, Rose,J.W.,et al, 2007
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006
Infliximab and Reactivation of Cerebral Toxoplasmosis
NEJM 353:1530-1531, Callegari,P.E., 2005
Prolactinoma
NEJM 349:2035-2041, Schlechte,J.A., 2003
Onset of Multiple Sclerosis Associated With Anti-TNF Therapy
Neurol 57:1885-1888, Sicotte,N.L. &Voskuhl,R.R., 2001
Interferon-alpha 2a Reduces MRI Disease Activity in Relapsing-Remitting Multiple Sclerosis
Neurol 52:1049-1056, Myhr,K.M.,et al, 1999
Neurologic Complications Associated with Hepatitis C Virus Infection
Neurol 53:861-864, Tembl,J.I.,et al, 1999
Clinicopath Conf,Sarcoidosis,with Involvement of Spinal Cord,Brain,Mediastinal Lymph Nodes and ? Lung,Case 35-1998
NEJM 339:1534-1541, , 1998
Bromocriptine and Postpartum Cerebral Angiopathy:A Causal Relationship
Neurol 46:1754-1756, Comabella,M.,et al, 1996
Chiasmal Herniation as a Complication of Bromocriptine Therapy
J Neuro-Ophthalmol 16:252-257, Taxel,P.,et al, 1996
Chronic Systemic High-Dose Recombinant Interferon Alfa-2a Reduces Exacerbation Rate & MRI Signs in MS
Neurol 44:406-413, Durelli,L.,et al, 1994
Diagnosis and Management of Pituitary Tumours
BMJ 308:1087-1091, Levy,A.&Lightman,S.L., 1994
Diagnosis and Management of Hormone-Secreting Pituitary Adenomas
NEJM 324:822-831, Klibanski,A.&Zervas,N.T., 1991
Acromegaly
NEJM 322:966-977, Melmed,S., 1990
MR Imaging of Pineal Tumors
AJR 155:143-151, Tien,R.D.,et al, 1990